iRhythm TechnologiesIRTC

We expect revenue to grow from $0.9B in FY2026 to $2.0B in FY2031 (~18% CAGR), with EPS growing from $0.00 to $9.50. Growth is driven by the Zio cardiac monitor expanding into international markets and the Verily partnership for atrial fibrillation screening. Profitability improves as the fixed costs of the cloud-based data platform are spread across a much larger volume of patient tests. EPS grows faster than revenue because the company has passed its Operating margin expected to reach ~25% by FY2031.

International expansion adds a second major growth engine. Expanding into the UK and Japan allows iRhythm to replicate its U.S. success in massive untapped markets.

Primary care screening unlocks a massive new patient population. Moving from specialized cardiology to general screening for high-risk patients multiplies the addressable market by 5x to 10x.

AI-driven efficiency drives EBITDA margins toward 20%. Further automating the heartbeat analysis process reduces the need for human technicians and expands profitability.

Large med-tech incumbents use bundling to pressure pricing. Companies like Boston Scientific could offer monitoring patches at lower prices as part of larger hospital supply contracts.

Reimbursement rate cuts from CMS damage per-unit profitability. Any structural change in how Medicare pays for cardiac monitoring would directly hit iRhythm's high-margin revenue stream.

Data privacy regulations limit AI training on patient records. New laws restricting the use of patient data for algorithm development could stall iRhythm's accuracy advantage.

Detailed deep dive on earnings update reports will be available soon for Pro members.

We use a 5-year Discounted Cash Flow (DCF) with a terminal value based on a 30x exit multiple. This framework fits iRhythm because the company is at a profitability inflection point, where current earnings are less important than the multi-year trajectory of cash flow expansion as the platform scales.

The headline math sums the present value of cash flows through 2030 and a terminal value ($5.2B), less net debt, divided by 32 million shares. Our 30x exit multiple sits at the mid-point of medical technology peers (Dexcom at 35x, Insulet at 32x, and established med-tech at 22x). This position is justified by iRhythm's faster revenue growth compared to the mature group. We used the deterministic engine's FY2031 EPS projection of $9.50 as the basis for our terminal value calculation to ensure internal consistency.

Cross-checked with a peer-anchored Forward P/E (FY2028 EPS $2.40 multiplied by a 60x high-growth multiple), we get a 2028 value of $144, which discounts back to $115 today. This is roughly 30% below our DCF answer of $165. This disagreement occurs because the DCF captures the massive expected step-up in profitability between 2029 and 2031, while the P/E cross-check only looks at a single year of earnings. Given that iRhythm's value is tied to its long-term scaling potential, the DCF provides the more accurate fair value.

We're assuming operating margins expand from current losses to 20% by FY2030. This is reasonable because the company's fixed costs for clinical analysis centers will be spread across a much larger volume of diagnostic tests as adoption scales, a trend already visible in the 25% revenue growth.

We're assuming a 12% Discount Rate (WACC) to account for the company's high volatility. This rate incorporates a beta of 1.51, which reflects that the stock moves more sharply than the broader market, and provides a necessary margin of safety for a business that is not yet consistently profitable.

We're assuming the business sustains a 30x exit multiple in our terminal year of FY2031. This matches the deterministic engine's benchmark and is consistent with other high-growth medical technology leaders that dominate their specific diagnostic niche.

The biggest risk is a sudden reduction in reimbursement rates from the Centers for Medicare and Medicaid Services (CMS). This would compress gross margins from 71% toward 60%, knocking roughly $45 off the per-share fair value and delaying GAAP profitability by several years. Watch the annual CMS Physician Fee Schedule updates in July for any early signs of pricing pressure.